RA'ANANA, Israel, Aug. 13,
2024 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira,"
"Inspira Technologies," or the "Company"), a trailblazer in
life-support technology, today announced that it was approached by
a leading medical technology company in the industry, to evaluate
the operation of its proprietary key product in combination with
the INSPIRA™ ART100 system. The evaluation was conducted by Inspira
researchers. The test results exceeded 100% of the standard value
for gas transfer at maximum flow, as indicated in the product's
specification when integrated with the INSPIRA™ ART100 system.
The evaluation tests were conducted in Inspira's advanced
laboratory, adhering to rigorous regulatory guidelines. The process
involved a setting that enabled continuous, real-time management of
blood parameters across various blood flow rates, simulating
oxygen-deficient and carbon dioxide-rich blood post-circulation
through body organs and tissues. This series of evaluations
confirmed that the integrated system met the specified
requirements, performing to expectations without any technical
malfunctions or abnormal effects on the blood.
We believe that the successful test results are a clear
indication of the power and versatility of the INSPIRA™ ART100
system when used in various settings of technologies. The INSPIRA™
ART100 system's unique design and advanced capabilities provide a
comprehensive platform of efficiency, compatibility and
performance, enabling medical technologies companies to refine and
optimize the products for improved patient care.
Dagi Ben-Noon, CEO of Inspira Technologies, stated, "We
believe that this successful evaluation validates the INSPIRA™
ART100 system's compatibility and performance with key products of
a leading medical technology company. I believe that this further
indicates that industry players are acknowledging our growing
capabilities and that we have the potential to translate these
capabilities into meaningful business development activities."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies targets to reshape the respiratory
and life-support landscape. We are developing novel expanding life
support technologies with Inspira blood oxygenation and blood
monitoring technologies. Inspira is on a quest to become the
leading ground-breaking medical device company in our field with
business alliances around the world.
The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500,
will include the Company's Adaptive Blood Oxygenation technology
and is being designed to continuously measure the patient's blood
parameters in real-time, delivering needed oxygen volume straight
into the blood. By elevating patient oxygen saturation levels in
minutes, this technology potentially allows patients to remain
awake during treatment and therefore may enable patients to be
treated in and beyond intensive care units, reducing the need for
mechanical ventilation systems that require intubation and
medically induced coma.
The Company's INSPIRA™ ART100 system received FDA 510(k)
clearance for Cardiopulmonary Bypass procedures and AMAR
certification for Extra-Corporeal Membrane Oxygenation and
Cardiopulmonary Bypass procedures.
The Company's other products, including the INSPIRA™ ART (Gen 2)
including the INSPIRA Cardi-ART portable modular device and HYLA™
blood sensor are currently being designed and developed, and have
not yet been tested or used in humans and have not been approved by
any regulatory entity.
For more information, please visit our corporate
website: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the belief that the
successful test results are a clear indication of the power and
versatility of the INSPIRA™ ART100 system when used in various
settings of technologies, that the INSPIRA™ ART100 system's unique
design and advanced capabilities provide a comprehensive platform
of efficiency, compatibility and performance, enabling medical
technologies companies to refine and optimize the products for
improved patient care, that this evaluation validates the INSPIRA™
ART100 system's compatibility and performance with key products of
a leading medical technology company, and the belief that this
further indicates that industry players are acknowledging its
growing capabilities and its potential to translate these
capabilities into meaningful business development activities. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All
rights reserved.
For more details:
Adi Shmueli
Public Relations Manager
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-approached-by-large-medical-company-to-evaluate-operation-of-their-key-product-with-inspira-art100--results-exceed-100-at-maximum-flow-302221019.html
SOURCE Inspira Technologies
